Advances in Systemic Treatment of Breast Cancer (Review)
Take-home: Since 2020, systemic #BreastCancer therapy has advanced through targeted treatments, antibody–drug conjugates, immunotherapy, and biomarker-guided strategies. CDK4/6 inhibitors remain central in hormone receptor–positive disease, while novel agents address endocrine resistance. Trastuzumab deruxtecan is reshaping HER2-positive treatment, and immunotherapy benefits selected triple-negative cases. Precision medicine increasingly supports risk-adapted treatment. Key challenges include optimizing sequencing, refining predictive biomarkers, integrating circulating tumor DNA, and ensuring equitable access to innovative, often costly therapies.
About this highlight
- Type
- Publication pick
- Topic
- Breast
